Answers are grounded in this paper and cite their sources.
Background: The optimal hemoglobin (Hb) target in patients with chronic kidney disease (CKD) treated with erythropoietin (EPO) has not been established.The prevalent view is that normalization of Hb increases the risk of death and cardiovascular (CV) events.Methods: The impact of baseline hematocrit (Htc) on survival and CV complications was evaluated in 1591 hemodialysis patients treated with EPO.Patients were classified into five Htc groups: Group 1: < 30%; Group 2: ≥ 30-35%; Group 3: > 35-40%; Group 4: > 40-45%; Group 5: > 45%.End-points were all-cause, CV, and coronary mortality, and major CV events.Results: Patients with lower Htc (< 30%) had a reduced survival compared to patients with the higher (> 45%) Htc (p=0.009,HR=2.02, % CI 1.19-3.42).Age (HR 1.03 %CI 1.02-1.04p=0.0001), diabetes (HR 1.99, %CI 1.56-2.35p=0.0001), associated CV disease (HR 1.63 %CI 1.28-1.79p=0.0001), left ventricular mass index (HR 1.003 %CI 1.001-1.003p=0.004), and Htc < 30% (HR 1.92 %CI 1.03-3.57p=0.039) were the independent predictors of all-cause mortality.The incidence of CV and coronary death and CV events did not differ among groups.Conclusion: Normal or above-normal Htc was associated with better survival compared to Htc<30% in patients treated with EPO, suggesting that complete correction of anemia may not be harmful in some selected groups of patients.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: